GB201918963D0 - Polymeric nanoparticles as vaccine adjuvants - Google Patents

Polymeric nanoparticles as vaccine adjuvants

Info

Publication number
GB201918963D0
GB201918963D0 GBGB1918963.8A GB201918963A GB201918963D0 GB 201918963 D0 GB201918963 D0 GB 201918963D0 GB 201918963 A GB201918963 A GB 201918963A GB 201918963 D0 GB201918963 D0 GB 201918963D0
Authority
GB
United Kingdom
Prior art keywords
polymeric nanoparticles
vaccine adjuvants
vaccine
adjuvants
nanoparticles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1918963.8A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
College of the Holy and Undivided Trinity of Queen Elizabeth near Dublin
Original Assignee
College of the Holy and Undivided Trinity of Queen Elizabeth near Dublin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by College of the Holy and Undivided Trinity of Queen Elizabeth near Dublin filed Critical College of the Holy and Undivided Trinity of Queen Elizabeth near Dublin
Priority to GBGB1918963.8A priority Critical patent/GB201918963D0/en
Publication of GB201918963D0 publication Critical patent/GB201918963D0/en
Priority to US17/787,051 priority patent/US20230218752A1/en
Priority to PCT/EP2020/087456 priority patent/WO2021123430A1/en
Priority to CA3162350A priority patent/CA3162350A1/en
Priority to AU2020407306A priority patent/AU2020407306A1/en
Priority to CN202080097299.0A priority patent/CN115279401A/zh
Priority to EP20841918.4A priority patent/EP4076519A1/en
Priority to JP2022538064A priority patent/JP2023507497A/ja
Priority to JP2025189065A priority patent/JP2026015426A/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/25—Varicella-zoster virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
GBGB1918963.8A 2019-12-20 2019-12-20 Polymeric nanoparticles as vaccine adjuvants Ceased GB201918963D0 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
GBGB1918963.8A GB201918963D0 (en) 2019-12-20 2019-12-20 Polymeric nanoparticles as vaccine adjuvants
US17/787,051 US20230218752A1 (en) 2019-12-20 2020-12-21 Polymeric nanoparticles as vaccine adjuvants
PCT/EP2020/087456 WO2021123430A1 (en) 2019-12-20 2020-12-21 Polymeric nanoparticles as vaccine adjuvants
CA3162350A CA3162350A1 (en) 2019-12-20 2020-12-21 Polymeric nanoparticles as vaccine adjuvants
AU2020407306A AU2020407306A1 (en) 2019-12-20 2020-12-21 Polymeric nanoparticles as vaccine adjuvants
CN202080097299.0A CN115279401A (zh) 2019-12-20 2020-12-21 聚合物纳米颗粒作为疫苗佐剂
EP20841918.4A EP4076519A1 (en) 2019-12-20 2020-12-21 Polymeric nanoparticles as vaccine adjuvants
JP2022538064A JP2023507497A (ja) 2019-12-20 2020-12-21 ワクチンアジュバントとしてのポリマーナノ粒子
JP2025189065A JP2026015426A (ja) 2019-12-20 2025-11-10 ワクチンアジュバントとしてのポリマーナノ粒子

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1918963.8A GB201918963D0 (en) 2019-12-20 2019-12-20 Polymeric nanoparticles as vaccine adjuvants

Publications (1)

Publication Number Publication Date
GB201918963D0 true GB201918963D0 (en) 2020-02-05

Family

ID=69322661

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1918963.8A Ceased GB201918963D0 (en) 2019-12-20 2019-12-20 Polymeric nanoparticles as vaccine adjuvants

Country Status (8)

Country Link
US (1) US20230218752A1 (https=)
EP (1) EP4076519A1 (https=)
JP (2) JP2023507497A (https=)
CN (1) CN115279401A (https=)
AU (1) AU2020407306A1 (https=)
CA (1) CA3162350A1 (https=)
GB (1) GB201918963D0 (https=)
WO (1) WO2021123430A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114657210B (zh) * 2022-03-03 2023-08-11 中山大学孙逸仙纪念医院 一种基于负载gsdmd蛋白n端肽段的纳米材料及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599230A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4601903A (en) 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
JP4526708B2 (ja) 1998-09-01 2010-08-18 メリオン リサーチ スリー リミテッド 細胞を媒介した免疫応答を誘導する方法及びそのための非経口ワクチン製剤
US8021689B2 (en) * 2006-02-21 2011-09-20 Ecole Polytechnique Federale de Lausanne (“EPFL”) Nanoparticles for immunotherapy
US8323696B2 (en) * 2008-08-29 2012-12-04 Ecole Polytechnique Federale De Lausanne Nanoparticles for immunotherapy
JP6008345B2 (ja) 2009-02-27 2016-10-19 東レ株式会社 免疫原性組成物
US9572894B2 (en) 2010-10-18 2017-02-21 The University Of Iowa Research Foundation Biodegradable particulate formulations
CN104338126B (zh) * 2013-08-08 2018-05-04 中国科学院过程工程研究所 一种具有治疗或预防hpv病毒的疫苗组合物及其应用
US10117886B2 (en) 2014-05-30 2018-11-06 Hao Cheng Hyaluronidase and a low density second PEG layer on the surface of therapeutic-encapsulated nanoparticles to enhance nanoparticle diffusion and circulation
MX2018010586A (es) * 2016-03-02 2019-03-28 Univ Texas Nanovacuna de activacion de "sting" para inmunoterapia.
US11925693B2 (en) * 2017-07-27 2024-03-12 The Board Of Trustees Of The Leland Stanford Junior University Polymeric nanoparticles for enhanced cancer immunotherapy

Also Published As

Publication number Publication date
JP2023507497A (ja) 2023-02-22
JP2026015426A (ja) 2026-01-29
CA3162350A1 (en) 2021-06-24
EP4076519A1 (en) 2022-10-26
AU2020407306A1 (en) 2022-07-07
US20230218752A1 (en) 2023-07-13
WO2021123430A1 (en) 2021-06-24
CN115279401A (zh) 2022-11-01

Similar Documents

Publication Publication Date Title
GB202010425D0 (en) Combination vaccine
GB202002166D0 (en) Vaccine
ZA201607627B (en) Vaccine composition against streptococcus suis infection
GB201616007D0 (en) Novel Adjuvants
IL304441A (en) Measles-hiv or measles-htlv based vaccine
GB2562241B (en) Vaccine compositions
GB201704417D0 (en) Improved li vaccine adjuvant
GB201910794D0 (en) Vaccine
EP3166957A4 (en) Sulfated-glycolipids as adjuvants for vaccines
GB201918963D0 (en) Polymeric nanoparticles as vaccine adjuvants
GB201811382D0 (en) Vaccine
GB202112149D0 (en) Shigellla vaccine
GB201703529D0 (en) Vaccine composition
GB201621396D0 (en) Adjuvants
GB201618479D0 (en) Adjuvants
GB202016954D0 (en) Vaccine
PT3297666T (pt) Adjuvante e vacina molecular
GB201911636D0 (en) Vaccine
GB201718251D0 (en) Vaccine Compositions
GB201621375D0 (en) Adjuvants
GB202119115D0 (en) Vaccine
GB202118110D0 (en) Vaccine
GB202114274D0 (en) SARS-CoV-2 vaccine
GB202102677D0 (en) Vaccine
GB202016165D0 (en) Vaccine

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)